Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation and stopping of imatinib, nilotinib, or dasatinib in chronic myeloid leukemia
ISRCTN74084226Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Aug 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of imatinib, nilotinib and dasatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by University of Liverpool. Primary endpoint: Proportion of patients who can de-escalate and stop TKI without losing major molecular response. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN74084226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN74084226.